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Introduction
Melanoma is an immunogenic tumor, and the presence of his-
topathologically detected tumor-infiltrating lymphocytes (TILs) 
is associated with increased patient survival and reduced risk of 
metastasis (1). For stage IV melanoma, patient outcomes can be 
improved through the use of immunotherapy. PD-1 blockade is 
the best-tolerated and most effective drug treatment so far (2), 
but it only benefits approximately 35% of patients (3–5). This, 
coupled with the potential for severe side effects, highlights the 
need to identify those patients whose outcomes will be improved 
using alternative regimes (6). In an attempt to better understand 
the drivers of antimelanoma immune responses, we have char-
acterized the transcriptomes from a large collection of primary 
tumors in a treatment-naive population. It is our hypothesis that 
the identification of these subgroups will be of benefit in predict-
ing responses to immunotherapy and other targeted therapies.
Predictive biomarkers using archival tumor tissue are desir-
able, but degraded RNA/DNA has been identified as one of the 
major challenges to genomic studies (7). Transcriptomic tumor 
profiling and bioinformatic imputation have recently allowed the 
categorization of the immune component (immunome) of tumors 
(8, 9), in which the presence of different proportions of tumor-
infiltrating immune cells is inferred from the overrepresentation 
of transcripts specific to particular immune cell types. Here, we 
have used a modification of this technique to characterize the het-
erogeneous immune landscape in 703 primary cutaneous mela-
nomas from a population-ascertained cohort (the Leeds Mela-
noma Cohort [LMC]) (10, 11) and examined whether the inferred 
immune subgroups reflect patient survival characteristics. We 
have coupled this with an analysis of candidate immune evasion 
pathways and correlations with driver oncogene mutations and 
tested our findings in a second data set from The Cancer Genome 
Atlas (TCGA), which includes primarily metastatic tumors (n = 
369) with a subset of primaries (n = 103). Our results highlight sub-
stantial heterogeneity in the immune landscape across melanoma 
primaries and metastases and show evidence for immune inhibi-
tion by β-catenin signaling in a significant proportion of tumors.
Results
Whole transcriptomes were derived from 703 formalin-fixed par-
affin wax–embedded (FFPE) primary cutaneous melanomas from 
the LMC (median follow-up, 7.5 years), using the Illumina DASL 
HT12.4 array. These data were normalized, then randomly divided 
into training (two-thirds) and test sets (one-third) (see Methods, 
Supplemental Table 1, and Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/
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atin poor (CIC3). Four groups of genes (Figure 1A; see Methods for 
more details) defined these clusters, 2 groups of which appeared 
as the most discriminant (G1 and G3; Figure 1A). Each gene clus-
ter was enriched in expression of genes attributed to particular 
immune cell subtypes (Supplemental Figure 4). G1 was strongly 
enriched in genes characteristic of innate immune cells such as 
macrophages (P = 0.001), mast cells (P = 10–8), and immature 
DCs (P = 2 × 10–5); G3 was strongly enriched in genes associated 
with adaptive immunity (cytotoxic cells, P = 4 × 10–5, and T cells, 
P = 2 × 10–8), and G4 was enriched in genes attributed to natural 
killer (NK) CD56bright cells (P = 2 × 10–4). These P values (derived 
from Fisher’s exact test) were all, except for macrophages in G1, 
below 5.2 × 10–4, which corresponds to 0.05 corrected for multiple 
testing using the conservative Bonferroni method (24 cell types × 
4 gene clusters = 96 tests). In addition to adaptive immunity, G3 
had a nominal overrepresentation of genes attributed to 2 innate 
immune cells, activated DCs (aDCs; P = 0.05) and NK CD56dim 
cells (P = 0.007), although this overrepresentation did not hold up 
upon multiple-testing adjustment. G2 had nominally significant 
JCI95351DS1). The definition of the immunome originally devel-
oped for application to colorectal cancer (8) was adapted to mela-
noma by the filtering out of genes expressed by melanoma and 
melanocyte cell lines, resulting in a set of 380 genes specific to 24 
immune cell types, referred to herein as the “Melanoma Immu-
nome” (see Methods). The gene list, inferred immune cells, 
immunity type (innate or adaptive), and relationship between 
some of these cells as reported by Bindea et al. (8) are summarized 
in Supplemental Table 2 and Supplemental Figure 2.
Consensus cluster analysis. Using primary tumor transcrip-
tomes, we conducted consensus cluster analysis (12, 13) of the 
training sample set (see Methods and Supplemental Figure 3). 
This revealed 6 distinct subgroups reproducible in the test data set 
and referred to herein as consensus immunome clusters (CICs) 
(Figure 1A). Examination of the molecular characteristics of these 
CICs (see below) allowed us to further characterize them as high 
immune (CIC2), low immune/keratin rich (CIC6), low immune/ 
β-catenin high (CIC4), intermediate immune/keratin rich (CIC5), 
low immune/β-catenin low (CIC1), and intermediate immune/ker-
Figure 1. Tumor classification. (A) Consensus immunome clusters (CICs) in the LMC training (n = 465) and test (n = 238) data sets ordered according to 
the dendrogram output from ConsensusClusterPlus (see Supplemental Figure 3). The details of gene clusters G1–G4 are given in Supplemental Figure 4. 
(B) Differential melanoma-specific survival for patients with tumors in the 6 CICs in the training, test, and pooled data sets unadjusted for histological 
factors. Cluster size: 11%, 21%, 13%, 25%, 15%, and 15% for CICs 1–6, respectively. Cause of death was unknown or was not melanoma for 27 patients, and 
they were excluded from survival analysis.
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whole tumor and the cored area of tumor, as graded blindly by a 
single observer (S. O’Shea) (see Supplemental Figure 5 for exam-
ples of TIL grading), showed a similar relationship with CICs (Sup-
plemental Table 3). The hazard ratio (HR) for melanoma death 
was 1.7 (P = 0.004) for low immune/β-catenin high (CIC4) versus 
the remaining CICs after adjustment for 7 other prognostic factors 
(Table 2). The results were maintained when the American Joint 
Committee on Cancer (AJCC) stage was replaced by ulceration 
and Breslow thickness in multivariable analyses (Supplemental 
Table 4). The prognostic effect of CICs was much stronger than 
that of CD8A or CD8B expression alone (Supplemental Table 4).
Despite similar survival profiles, the tumors represented with-
in CICs 1, 2, 3, and 5 and 6 had heterogeneous immune signatures 
(Figure 1A) and clinicopathological features. High immune (CIC2) 
was characterized by higher expression of immune signaling genes 
(in particular, cytotoxic cell genes) compared with intermediate 
immune/keratin poor (CIC3) and intermediate immune/keratin 
rich (CIC5), and yet this appeared to bestow no survival advantage 
(Figure 1B). Low immune/β-catenin low (CIC1) was the smallest 
overrepresentation of genes attributed to CD8+ T cells (P = 0.005), 
central memory T cells (P = 0.02), Th2 cells (P = 0.05), and eosino-
phils (P = 0.03) (Figure 1A and Supplemental Figure 4).
High immune (CIC2) and intermediate immune/keratin 
poor (CIC3) notably overlapped with “high immune” phenotypes 
inferred using signatures reported by Jonsson et al. and TCGA 
(14–16), and low immune/β-catenin high (CIC4) overlapped with 
“pigmentation,” “proliferative,” and “MITF.low,” while interme-
diate immune/keratin rich (CIC5) and low immune/keratin rich 
(CIC6) overlapped with “normal-like” and “keratin” phenotypes 
(Supplemental Figure 4).
Tumors classified as high immune (CIC2) were also those 
most frequently classified as having “brisk” TILs (34%) by the 
dermatopathologists who generated the biopsy reports (Table 
1), while those tumors classified as low immune/β-catenin high 
(CIC4) presented with far fewer pathologist-reported brisk TILs 
(7%; Table 1), and this was associated with significantly worsened 
melanoma-specific survival (training set: P = 2 × 10–5; test set: 10–4; 
pooled data, P = 2 × 10–8; Figure 1B). The presence of TILs in the 
Table 1. Association between the 6 CICs and clinicohistological features of the tumors in the pooled data set
CIC1 CIC2 CIC3 CIC4 CIC5 CIC6 P A P B P C P D
Number of tumors 77 147 89 175 110 105 – – – –
Melanoma death (%) 23.7 20.1 30.2 48.5 23.1 27.5 4.2 × 10–7 0.47 2.3 × 10–7 0.005
Age at diagnosis (median, years) 56.7 58.2 59.7 60.3 57.8 50.6 1.6 × 10–5 0.004 0.01 0.31
Site (% of tumors on limbs) 52.0 45.6 40.4 33.1 41.8 48.6 0.04 0.52 0.02 0.24
Sex (% males) 48.0 46.3 55.1 49.7 41.8 29.5 0.007 0.006 0.54 0.41
BRAF-mutated (%) 55.2 45.6 44.6 36.7 59.3 50.7 0.01 0.41 0.13 0.24
NRAS-mutated (%) 24.6 19.3 30.5 30.6 16.3 26.0 0.09 0.24 0.04 0.98
Ulcerated (%) 37.7 23.8 51.7 49.1 16.4 20.0 3.9 × 10–12 5.2 × 10–7 2.9 × 10–6 0.70
Breslow thickness (median, mm) 2.3 2.0 2.7 3.2 1.8 1.8 8.5 × 10–19 5.8 × 10–7 1.8 × 10–10 0.05
Mitotic rate (median, count/mm2) 2.5 2.5 4.8 6 1.5 3 2.8 × 10–13 0.004 2.3 × 10–9 0.01
AJCC stage (%)
 I 31.1 41.5 15.7 16.4 51.4 48.6 4.8 × 10–11 8.0 × 10–5 2.7 × 10–6 0.42
 II 51.3 46.3 68.6 61.4 40.4 37.1
 III 17.6 12.2 15.7 22.2 8.3 14.3
TILs (%)E
 Brisk 10.0 34.1 13.0 6.9 10.0 8.4 9.2 × 10–12 6.8 × 10–7 5.8 × 10–11 0.002
 Non-brisk 58.0 48.8 70.1 67.7 71.1 55.4
 Unclassified 18.0 13.0 10.4 3.1 7.8 12.1
 No TILs 14.0 4.1 6.5 22.3 11.1 24.1
AComparison of all 6 CICs; Bcomparison of all CICs except CIC4; CCIC2 vs. CIC4; DCIC3 vs. CIC4; ETILs as measured by dermatopathologists in clinic.
Table 2. Prognostic value of the CICs in univariable and multivariable analyses of pooled LMC data set (Cox regression)
Characteristic adjusted CIC4 vs. CIC2 CIC4 vs. all others
HR (95% CI)A P HR (95% CI)A P
– 3.0 (1.92, 4.53) 8.1 × 10–7 2.5 (1.88, 3.29) 1.8 × 10–10
Age, sex, tumor site 2.5 (1.59, 3.81) 5.7 × 10–5 2.1 (1.58, 2.79) 3.2 × 10–7
Age, sex, site, AJCC, mitotic rate 2.0 (1.22, 3.21) 0.005 1.8 (1.33, 2.54) 2 × 10–4
Age, sex, site, AJCC, mitotic rate, vascular invasion 1.9 (1.16, 3.19) 0.01 1.7 (1.21, 2.35) 0.002
Age, sex, site, AJCC, mitotic rate, vascular invasion, mutation statusB 1.8 (1.03, 3.19) 0.04 1.7 (1.18, 2.40) 0.004
AHazard ratio and 95% confidence interval for melanoma-specific survival. BBRAF and NRAS mutation status.
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Figure 2. Association of immune scores with evasion mechanisms. (A) Distribution of selected immune cell scores in 6 CICs (pooled training and test 
LMC, n = 703). (B) Correlation and ratio between adaptive and innate immune scores (LMC). Owing to the high correlation between adaptive and innate 
scores, their ratios show a little variation between CICs. In A and B, R2 is the proportion of variance explained by the 6 CICs computed in ANOVA. Dot plots 
are shown alongside box plots showing the median and the interquartile range. (C) Correlations in LMC and TCGA (n = 472) between (a) 5 cell scores; (b) 
checkpoint and other regulatory genes; (c) β-catenin signaling genes; and (d) keratin and filaggrin expression. Based on the immune genes and keratin 
expression, the 6 CICs were described as low immune/β-catenin low (CIC1), high immune (CIC2), intermediate immune/keratin poor (CIC3), low immune/ 
β-catenin high (CIC4), intermediate immune/keratin rich (CIC5), and low immune/keratin rich (CIC6).
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relative excess of Tregs in low immune/β-catenin 
low (CIC1), and although Th2 did not vary much 
between the CICs, the Th1/Th2 ratio was lowest 
in low immune/β-catenin high CIC4 in conjunc-
tion with the lowest immune score. Consistent 
with the results from consensus classification 
(Figure 1A), the correlation between innate and 
adaptive immune scores was weaker within inter-
mediate immune/keratin poor CIC3 and interme-
diate immune/keratin rich CIC5 compared with 
the rest (Figure 2B).
Genes encoding PD-1, PDL-1, PDL-2, 
CTLA4, TIM-3, LAG3, VISTA, BTLA, IDO1, 
IDO2, ICOS, CD27, and CD72 had their high-
est expression in the tumors with the strongest 
T cell infiltration (Figure 2C), while CD200 had 
no clear association with CICs. Immunostimula-
tory transcription factors encoded by IRF8 and BATF3 were also 
highly correlated with both T cell and aDC scores, as was expres-
sion of CCR7 and CCL4L1 (Figure 2C).
The expression of CTNNB1 (encoding β-catenin) and its down-
stream targets such as TCF12, APC2, SOX2, SOX11, and MYC was 
inversely correlated with T cell cytotoxicity scores (Figure 2C) with 
up to 1.8-fold higher levels in CIC4 compared with CIC2 (Supple-
mental Table 6). A score for the β-catenin signaling pathway based 
on these genes was significantly different between CICs and was 
strongly negatively correlated with the T cell score (Spearman R = 
–0.43, compared with R = –0.31 between T cell score and CTNNB1 
expression). In contrast, the genes coding for inhibitors of this 
pathway such as DKK2 and DKK3 were upregulated in the good-
prognosis groups high immune (CIC2) and intermediate immune/
keratin rich (CIC5). E-cadherin plays a role in posttranscriptional 
regulation of β-catenin, and we postulated it might reduce the 
immunoinhibitory effect of β-catenin; we found its expression 
weakly but positively correlated with that of β-catenin (Figure 2C; 
Spearman R = 0.15). We found no evidence that the ratio between 
E-cadherin and β-catenin expression more strongly correlated with 
T cell infiltration (data not shown). We used X-tile (17) to identify 
cut points in CTNNB1 expression best predicting reduction in T cell 
score, and from this analysis we calculated that 59% of immune 
low/β-catenin high CIC4 tumors exceeded this level compared 
with only 30% of the total population-based cohort (Fisher’s exact 
P = 6 × 10–21). A similar analysis based on β-catenin pathway score 
indicated that 42% of the cohort have upregulation of the pathway, 
but this figure was 73% in CIC4 (Fisher’s exact P = 3 × 10–21).
Replication. To validate our observations, we used the TCGA 
data set. The 6 CICs derived from the LMC were also visible in 
this independent data set and were found in both primaries and 
metastases. As in the LMC, CICs 2 and 4 were the largest, with 
160 tumors each, comprising both primaries and metastases 
(Table 4). CICs 6, 5, and 1 contained the largest proportion of pri-
mary tumors (61%, 50%, and 44%, respectively), although low 
immune/β-catenin low (CIC1) was very small, with only 9 tumors 
in total (Table 4). Similarly to the LMC, TCGA tumors classified 
within low immune/β-catenin high CIC4 were associated with 
the poorest survival (HR = 1.44, P = 0.01 for CIC4 vs. all others 
after adjustment for sex, age, and tumor type; see Table 5). All the 
cluster and appeared to be defined by genes from NK CD56bright 
cells and higher Treg scores (Figure 2A). CICs 1, 2, 3, 5, and 6 dif-
fered in median age at diagnosis, mitotic rate, Breslow thickness, 
gender, ulceration, and AJCC stage (Table 1). For example, only 
15.7% of tumors were diagnosed at AJCC stage I in intermediate 
immune/keratin poor CIC3, while this stage represents about 
50% of intermediate immune/keratin rich (CIC5). Further analy-
sis revealed that low immune/keratin rich (CIC6) actually had a 
poor outcome, comparable to that of the low immune/β-catenin 
high cluster (CIC4) (Table 3) when taking account of clinical fac-
tors, indicating that CIC6’s apparent good prognosis as seen in 
Figure 1A was driven by beneficial clinical factors. Particularly, 
despite very different prognoses, intermediate immune/kera-
tin poor (CIC3) (good survival) and low immune/β-catenin high 
(CIC4) (poor survival) were both associated with clinicopatho-
logical features well known to be associated with poor prognosis. 
Significantly, the key differences between the 2 clusters were the 
presence of histopathologically reported TILs (Table 1) and a tran-
scriptomic strong immune profile in intermediate immune/kera-
tin poor CIC3 (Figure 1A).
We had 9 paired transcriptomes from primaries and metas-
tases: 6 nodal and 3 soft tissue. CICs of these pairs are reported 
in Supplemental Table 5. Generally speaking, the immune status 
of the metastases was poorer than that of the primary tumor (par-
ticipants 1, 4, and 5) or equally poor (participants 7 and 9). In 3 
nodal metastases the data suggest a possible contamination of the 
tumor sample by nodal lymphocytes, and a keratin signature was 
observed in a cutaneous metastasis.
Immune cell scores. We generated immune cell scores by aver-
aging gene expression data attributed to each cell type (Supple-
mental Table 2) and used them to further compare CICs and 
explore immunomodulation. These scores varied strongly across 
CICs (Figure 2A), but the relative score differences were con-
sistent across the immune cell types. High immune CIC2 con-
sistently demonstrated the highest and low immune/β-catenin 
high CIC4 demonstrated the lowest scores for most immune cell 
types. The scores for Th2 cells, Tregs, and eosinophils exhibited 
the lowest variation between CICs. Although there was strong sta-
tistical evidence of an orchestrated immune response across clus-
ters, examination of the dot and box plots in Figure 2A shows a 
Table 3. Multivariable melanoma-specific survival analysis of the immunome 
clusters in the pooled LMC data set (Cox regression)
CIC Analysis 1A Analysis 2B
HR (95% CI) P value HR (95% CI) P value
2 1 Baseline 1 Baseline
1 1.26 (0.67, 2.34) 0.47 1.09 (0.58, 2.05) 0.79
3 1.17 (0.68, 2.03) 0.57 1.05 (0.60, 1.82) 0.87
4 2.03 (1.29, 3.21) 0.002 1.64 (1.02, 2.64) 0.04
5 1.06 (0.59, 1.90) 0.85 1.09 (0.60, 1.96) 0.78
6 1.76 (1.03, 3.02) 0.04 1.76 (1.03, 3.03) 0.04
AAdjusted factors: sex, age at diagnosis, tumor site, AJCC stage, vascular invasion; Badjusted 
factors: sex, age at diagnosis, tumor site, ulceration, Breslow thickness, vascular invasion. Table 
shows that CICs 4 and 6 have an equally poor survival when confounders are accounted for.
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observations made in the LMC regarding checkpoint molecules, 
immunosuppressive enzymes, and immunostimulatory transcrip-
tion factors were recapitulated in both primaries and metastases 
of the TCGA data set, i.e., the signatures for all these variables 
were most highly expressed in high immune CIC2 and repressed 
in low immune/β-catenin high CIC4 (Figure 2C). Similarly, the 
expression levels of the β-catenin pathway genes CTNNB1, TCF12, 
APC2, SOX2, SOX11, and MYC were all inversely correlated with 
immune scores in the TCGA data set, while their highest expres-
sion was also observed in low immune/β-catenin high CIC4 (Sup-
plemental Table 6). In a sensitivity analysis, all LMC and TCGA 
primaries were pooled into 1 data set, and a new consensus clus-
tering was conducted. The 6 tumor clusters and 4 gene clusters 
were again found (Supplemental Figure 7), indicating robustness 
of the approach used.
We additionally used melanoma TCGA methylation (n = 472), 
mutation (n = 287), and copy number variation (n = 367) data to 
examine the contribution of epigenetic and structural changes to 
the transcriptomic characteristics of CIC4. Overall, several genes in 
the β-catenin signaling pathway were amplified and/or had muta-
tions in a proportion of tumors (8% for APC, 7% for MYC, and 5% 
for CTNNB1), although the majority were putative passenger muta-
tions as shown in Figure 3A. There were, however, more amplifica-
tions (19/133) in low immune/β-catenin high CIC4 compared with 
the rest of the samples (12/235), with P = 0.002. Deletions (n = 5) 
and driver mutations (n = 15) were rarer and showed no association 
with clusters. It is noticeable from the OncoPrint graph (Figure 3A) 
that the majority of the alterations in the analyzed genes did not 
co-occur. As expected, expression of CTNNB1 itself and genes in 
the β-catenin signaling pathway was strongly negatively correlated 
with promoter methylation across all CICs (Spearman R = –0.58 to 
–0.22). Promoter methylation of β-catenin (CTNNB1) was mark-
edly lower in low immune/β-catenin high 
CIC4 compared with other clusters, in par-
ticular compared with high immune CIC2 
(P = 10–5; Figure 3B). A score combining 
expressions of 9 β-catenin signaling genes 
was associated with the tumor clusters (P 
= 2 × 10–17), and when methylation of these 
genes was further added, the association 
was stronger (P = 1.4 × 10–21) (Figure 3C). 
The contribution from putative activating 
mutations and copy number changes to the 
pathway score was comparatively weaker 
(Supplemental Figure 6).
Immune scores and driver mutation. By combining scores 
of 24 cell types of the immunome, we generated a mea-
sure of the total immune component of each tumor; these 
immune scores demonstrated good correlation with an 
overall immune score generated from the same data set 
using another scoring algorithm (Estimation of Stromal and 
Immune Cells in Malignant Tumors Using Expression Data 
[ESTIMATE]; ref. 18 and Figure 4A). When we applied pub-
lished melanoma molecular signatures (14, 15) to our data, 
we observed that tumors with the highest immune scores 
were also more likely to fall into molecular profiles previ-
ously characterized as high immune (Figure 4A). Multiple 
immune scores, including T cell, CD8+ T cell, cytotoxic cell, Th1, 
aDC, B cell, and total immune score, were highly prognostic in the 
LMC and were closely replicated in TCGA (Table 6). We sought 
to assess whether the most prevalent oncogenic mutations in 
BRAF (V600) and NRAS (codons 12, 13, and 61) may also mod-
erate immune responses. In the LMC, CD8+ T cell and NK cell 
scores were strongly predictive of melanoma-specific survival in 
double-WT tumors, but less so in BRAF-mutated and not at all in 
NRAS-mutated tumors (Figure 4B); these differences were not 
matched by differences in cell scores (Figure 1A). We observed no 
difference in pathologist-reported TILs between NRAS-mutated 
and WT tumors despite previous observations that NRAS-mutated 
melanoma primaries are less likely to have brisk TILs (19). Neither 
did we see evidence of higher CD274 (encoding PDL-1) in NRAS-
mutated tumors (20). The differential prognostic effect of CD8+ T 
and NK cell scores by driver mutation persisted when we adjusted 
for age, sex, site, and AJCC staging. Importantly, this observa-
tion was again confirmed in the metastatic tumors of TCGA (n = 
287), with the T cell score showing a similar distribution in BRAF-
mutated, NRAS-mutated, and double-WTs but showing no prog-
nostic effect in NRAS-mutated tumors (Figure 4C).
Protein data. In the next validation step, we conducted immu-
nohistochemical (IHC) staining of β-catenin and its membranous 
ligand E-cadherin in the cell membrane and of E-cadherin in a 
subset of the LMC data set (33 and 37 tumors, respectively). Fig-
ure 5A shows examples of tumors with “low” and “high” staining 
and the overall concordance between reported gene expression 
and the degree of IHC staining. Both β-catenin and E-cadherin 
were expressed only in tumor cells rather than stromal cells; 
E-cadherin was strongly expressed by tumor cells and epider-
mal cell membranes. There was a good agreement between gene 
expression and IHC staining of the protein for both genes, with 
Table 4. TCGA tumor types (primaries and metastases) in different 
clusters
Tumor type Consensus immunome cluster (CIC)
1 2 3 4 5 6 Total
Primary 4 15 3 27 18 36 103
Metastasis 5 145 45 133 18 23 369
Total 9 160 48 160 36 59 472
 
Table 5. Adjusted and unadjusted association between CICs and overall survival in TCGA 
data set (Cox regression)
Adjusted factor CIC4 vs. CIC2 CIC4 vs. all others
HR (95% CI) P HR (95% CI) P
– 1.42 (1.20, 1.68) 4 × 10–5 1.44 (1.10, 1.88) 0.01
Age 1.40 (1.19, 1.66) 10–4 1.41 (1.07, 1.84) 0.01
Age and sex 1.41 (1.19, 1.67) 10–4 1.40 (1.06, 1.83) 0.02
Age, sex, and tumor typeA 1.40 (1.19, 1.66) 10–4 1.44 (1.10, 1.90) 0.01
ATumor type: primary or metastasis.
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P = 0.02, 0.02, and 0.06 for overall, cytoplasmic, and membra-
nous β-catenin, respectively, and P = 0.004 for E-cadherin. We 
also downloaded the Reverse Phase Protein Array (RPPA) data 
from The Cancer Proteome Atlas for 354 of the 472 TCGA skin 
melanoma samples and compared these protein data with their 
corresponding gene expression for β-catenin, E-cadherin, LCK, 
and PDL-1. RPPA measures protein levels on a continuous scale, 
and Figure 5B shows that those values correlate well with mRNA 
expression (R = 0.25–0.83). As we observed in the gene expression 
data, low immune/β-catenin high CIC4 had a significantly higher 
protein expression of CTNNB1 (P = 0.02) and a lower expression 
of LCK (P = 10–26) and CD274 (PDL-1) (P = 10–14) compared with 
Figure 3. β-Catenin pathway regulation by mutations, copy number variation, and promoter methylation. (A) Plot of mutations, copy number variations 
(CNVs), mRNA expression, and promoter methylation in genes representing β-catenin pathway in TCGA data set. Figure shows the tumors with at least 1 
gene mutated or altered (n = 109) and genes affected by those changes in at least 4% of tumors. The samples (columns) are ordered from the most altered 
to the least altered. The top annotation bar represents 6 CICs. Fifty-five samples had at least 1 mutation, 44 at least 1 CNV; 5 had both. (B) Correlation 
between expression of CTNNB1 and its promoter methylation and statistical difference between CICs 2 and 4 (Mann-Whitney test). (C) A score combining 
expressions of 9 β-catenin signaling genes and their methylation has a higher correlation with the 6 CICs than a score from expression data alone (Kruskal-
Wallis). In B and C, the median and the interquartile range are shown in dot and box plots (n = 472).
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tumors. The sampling method allowed identification of transcrip-
tomic signals from the tumor environment, which was our intent, 
as tumor/host interaction is crucial in determining outcomes from 
this and other cancers. The sampling was carefully done, however, 
in order to compare one tumor with another. One weakness of the 
study is that there is some bias of sampling in that very thin pri-
maries were less likely to be sampled, although this is much less 
of a problem than in studies using fresh frozen samples. A second 
weakness is that using a tissue microarray (TMA) core may result 
high immune CIC2 (Figure 5B). Taken together, these IHC and 
RPPA data demonstrate concordance between gene expression 
and protein levels for these genes.
Discussion
This study has considerable strengths as it is derived from popu-
lation-ascertained melanoma patients, enabling more confident 
generalization of conclusions. The data set is one of the largest 
internationally and is unique in that it is derived from primary 
Figure 4. Immune score interaction with driver mutation. (A) Correlation between immunome total score in the LMC (n = 703) and its equivalent from 
ESTIMATE (18) and comparison with 2 published molecular signatures (14, 15). (B) Distribution of CD8+ T cell and NK cell scores and their association with 
melanoma-specific survival by driver mutation in LMC. (C) Association between T cell score and overall survival by driver mutation in TCGA data set (n = 
287). In B and C, the difference in immune cell scores (dot and box plots with median and interquartile range) does not explain the difference in survival. 
Cox proportional hazards model used in survival analyses; Kruskal-Wallis used to test score distribution by mutation status.
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are now in use) and therefore that transcrip-
tomic studies designed to identify predic-
tive biomarkers are now possible for tumor 
blocks stored from mature clinical trials. As 
the generation of sufficient RNA is possible 
now from single 5-μm slides, greater control 
of sampling should be possible. Finally, the 
most significant outcome, if we interpret our 
findings in the context of a general population 
of melanoma cases, was that CIC4, the worst-
prognosis group, which is the most prevalent 
of the 6 clusters, represents, we estimate, 
some 36% of stage III and 30% of stage II 
melanoma but only 12% of stage I melanoma.
Previous studies have shown an impor-
tant prognostic role played by immune activa-
tion in metastatic disease (21) and evidence 
that the identification of immune signa-
tures may have predictive value for check-
point blockade (22). Our study shows that 
immune signatures also predict survival in 
primary melanoma, offering hope that effi-
cient molecular predictive biomarkers can 
be derived for adjuvant immunotherapies. 
This is of relevance as survival benefit from 
ipilimumab as melanoma adjuvant therapy 
has been reported and the drug approved 
for adjuvant use in the United States. Recent 
comparison of nivolumab and ipilimumab as 
adjuvant therapies for resected stage III and 
IV melanoma has also been reported (23, 
24). We provide a detailed description of the 
immune landscape in tumors corroborated by 
histological evidence of TILs and inferences 
from other published tools (14, 15, 18) that we 
aim to develop and test in adjuvant clinical trials in order to iden-
tify predictive biomarkers.
The primary tumor clusters defined by immune profiles 
were strongly associated with histological characteristics such 
as Breslow thickness, mitotic rate, and ulceration, yet showed 
an independent prognostic value. As in previous reports (8, 21), 
we found that the tumors associated with the worst survival had 
gene expression patterns indicative of little cytotoxic T cell infil-
tration. We further found evidence specifically of fewer DCs, 
macrophages, and mast cells (Figure 1A and Supplemental Figure 
4). There are few published data relating to the role of mast cells 
in melanoma survival, but a small histochemical study recently 
reported that lower mast cell numbers were associated with 
melanoma progression (25). Arginase 1 and mast cell genes were 
upregulated in low immune/keratin rich (CIC6) and intermedi-
ate immune/keratin rich (CIC5), which were on average thinner 
and had predominantly “normal-like” and “keratin” phenotypes 
using previously described signatures (refs. 14–16 and Supple-
mental Figure 4). Since mast cells more commonly occur in the 
epidermis as does arginase 1 expression (Human Tissue Atlas; 
https://www.proteinatlas.org/), concern exists that this signature 
may reflect possible sampling of healthy skin.
in sampling of hair follicles with a recognizable site-specific signa-
ture such as some tumors classified in CIC5 and CIC6 (high kera-
tin and filaggrin expression). The identification of similar keratin 
signatures in Jonsson et al. (14) and TCGA (15) suggests, however, 
that this is an issue intrinsic to transcriptomic studies of this type 
irrespective of sampling method. The resulting data, we argue, are 
complementary to smaller-scale studies in which tumors are dis-
aggregated and then flow-cytometrically sorted in terms of under-
standing the biology of interactions between host and tumor.
A significant outcome of the study is that a single 0.6-mm 
diameter of FFPE tumor core was sufficient to generate array-
based transcriptomic data in 96.4% of tumors sampled; the qual-
ity of the data is evidenced by the strong correlation between 
inferred immune cell scores and the presence of brisk TILs report-
ed by specialist histopathologists and by a single observer in our 
research group. Moreover, we see very similar results from clusters 
identified in formalin-fixed primaries versus clusters identified 
in TCGA data, in which gene expressions were generated using 
RNA-Seq from fresh frozen tumor. In clinical biomarker develop-
ment terms, we anticipate that sampling of all but a small propor-
tion of very thin AJCC stage I tumors would be feasible from FFPE 
tumor (especially as arrays requiring very small amounts of RNA 
Table 6. Prognostic value of individual immune cell scores in LMC and TCGA data
Cell type LMC (primaries)A TCGA (80% metastatic)A
HR (95% CI)B P HR (95% CI)B P
T cell 0.54 (0.40, 0.71) 2 × 10–5 0.65 (0.49, 0.87) 0.004
Mast cell 0.53 (0.40, 0.70) 10–5 0.96 (0.71, 1.21) 0.76
Th2 cell 1.43 (1.08, 1.88) 0.01 0.80 (0.60, 1.06) 0.12
Eosinophil 1.46 (1.11, 1.93) 0.007 0.83 (0.62, 1.11) 0.22
Cytotoxic cell 0.58 (0.44, 0.76) 10–4 0.63 (0.47, 0.84) 0.002
CD8+ T cell 0.59 (0.45, 0.78) 2 × 10–4 0.59 (0.44, 0.79) 3 × 10–4
γδ T cell (Tgd) 0.73 (0.56, 0.97) 0.03 0.66 (0.49, 0.88) 0.005
Th1 cell 0.62 (0.47, 0.82) 0.001 0.52 (0.39, 0.70) 10–5
Th17 cell 0.59 (0.45, 0.78) 2 × 10–4 0.75 (0.56, 1.01) 0.06
Th cell 0.70 (0.53, 0.92) 0.01 0.75 (0.56, 1.00) 0.05
Follicular Th cell (Tfh) 0.58 (0.44, 0.77) 2 × 10–4 0.68 (0.51, 0.91) 0.01
Central memory T cell (Tcm) 0.52 (0.39, 0.69) 6 × 10–6 0.76 (0.57, 1.01) 0.06
Effector memory T cell (Tem) 0.66 (0.50, 0.87) 0.003 0.81 (0.61, 1.08) 0.16
Treg 1.09 (0.82, 1.43) 0.56 0.65 (0.49, 0.87) 0.004
B cell 0.58 (0.44, 0.77) 2 × 10–4 0.56 (0.41, 0.74) 7 × 10–5
Natural killer cell (NK) 0.84 (0.64, 1.11) 0.22 0.87 (0.65, 1.16) 0.33
NK CD56dim 0.74 (0.56, 0.97) 0.03 0.66 (0.49, 0.88) 0.005
NK CD56bright 1.02 (0.78, 1.34) 0.88 0.65 (0.48, 0.87) 0.004
DC 0.68 (0.52, 0.90) 0.007 0.68 (0.51, 0.91) 0.01
Activated DC (aDC) 0.63 (0.48, 0.84) 0.001 0.64 (0.48, 0.86) 0.003
Immature DC (iDC) 0.56 (0.42, 0.74) 6 × 10–5 0.79 (0.60, 1.07) 0.12
Plasmacytoid DC (pDC) 0.84 (0.64, 1.11) 0.23 0.86 (0.64, 1.15) 0.31
Macrophage 0.68 (0.51, 0.90) 0.007 0.71 (0.53, 0.95) 0.02
Neutrophil 0.81 (0.61, 1.06) 0.13 0.75 (0.56, 1.00) 0.05
Th1/Th2 ratio 0.64 (0.48, 0.84) 0.002 0.59 (0.43, 0.79) 4 × 10–4
Total immune score 0.62 (0.47, 0.82) 7 × 10–4 0.56 (0.42, 0.75) 4 × 10–4
AMelanoma-specific survival in the LMC, overall survival in TCGA. BHR from univariable Cox model 
with 95% CI for high versus low scores relative to the median. Bold type: significant at α = 0.002 in 
the LMC and replicated in TCGA at α = 0.05.
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Figure 5. Validation with IHC staining and protein data. (A) Representative images of IHC staining in the LMC demonstrating strong, moderate, and 
weak/negative expression of β-catenin localized to the nucleus (left column) and to the membrane (middle column) and expression of E-cadherin (right 
column) (CTNNB1 and CDH1 were stained in 33 and 37 tumors, respectively). Dot and box plots (median and interquartile range) show mRNA expression of 
CTNNB1 and CDH1 compared with IHC staining. (B) Protein (RPPA) data for LCK, PDL-1, CTNNB1, and CDH1 in TCGA skin melanomas (n = 354) in comparison 
with mRNA expression and CICs. Kruskal-Wallis test and Spearman correlation were used. Box plots show the median and the interquartile range.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
2 0 5 8 jci.org   Volume 128   Number 5   May 2018
good survival. This cluster is an unusual tumor group, as it was also 
associated with 52% tumors on the limbs (a good prognostic fac-
tor for melanoma), high BRAF driver mutation status (55%), yet 
a high frequency of tumor ulceration (38%; Table 1). The signifi-
cance of this group is as yet unclear.
The survival of low immune/β-catenin high CIC4 participants 
was worst, with low immune-keratin rich (CIC6) similarly poor 
when data were adjusted for histopathological features. The sur-
vival of the additional immune groups was, however, similar, and 
these were largely intermediate immune or high immune groups. 
The inference is that any immune response is valuable in terms of 
prognosis. Our hypothesis is, however, that these subgroups may 
respond differently to immunotherapy and therefore their identi-
fication may be of value in predictive marker studies.
Tumors circumvent immune responses in a number of ways 
(33, 34), and it is therefore important to identify key drivers of 
immune activation, immune evasion, and associated biomarkers. 
In this paper we present tumor expression of multiple checkpoint 
molecules that function in health to mitigate adverse effects of 
excess immune response. That immune activation promotes the 
expression of coinhibitory signals in tumors and predicts better 
outcome is well described (35). Our data therefore reflect the effi-
cacy of T cell responses in the majority, although there was some 
variation between tumor clusters in the patterns of expression of 
these molecules. In high immune CIC2 (greatest T cell scores), 
there was remarkable uniformity in expression of the vast major-
ity of immune checkpoint genes, consistent with the suggestion of 
redundancy (36), although this has been contested (37). In inter-
mediate immune CICs 3 and 5, accordingly, there was weaker 
expression of checkpoint molecules but with variation between 
groups: intermediate immune/keratin rich CIC5 had more VSIR 
(encoding VISTA) and HAVCR2 (TIM-3) mRNA. In low immune/
β-catenin high CIC4 (worst outcome and weak T cell infiltration), 
there was little evidence of immune failure as a result of primary 
upregulation of checkpoint molecules overall. It was notable that 
in the overwhelming majority of tumors in both the LMC and 
TCGA, multiple checkpoint molecules appeared coordinately 
elevated in response to T cell infiltration, adding support to recent 
clinical observations that combining checkpoint therapies may 
outperform monotherapy (38). The variation seen is, however, 
sufficient to argue that this variation should be tested as a poten-
tial predictive biomarker of response to checkpoint blockade.
Significant variation in expression of ARG1 (arginase-1) 
and ARG2 (arginase-2) was seen (Figure 2C). ARG1 was mostly 
upregulated in keratin rich CICs 5 and 6, while ARG2 was mostly 
upregulated in low immune/β-catenin CIC4. Since CICs 4 and 6 
have the weakest immune responses, this observation is consis-
tent with previous reports that arginase may perturb T cell activity 
by depleting the arginine in the milieu (39), thus promoting tumor 
growth (40, 41). However, as stated earlier, ARG1 may be derived 
from the epidermis and not play a relevant immunosuppressive 
role. ARG2 is not reported by the Human Protein Atlas (https://
www.proteinatlas.org/) as generally expressed in melanoma cells; 
therefore, this signal is likely to be coming from stromal cells in 
low immune/β-catenin high CIC4. Arginase 2 is reported to be 
synthesized by cancer-associated fibroblasts (CAFs) in pancre-
atic cancer (42), and our data would thus suggest a possible role 
Activation of T cells by DCs is required to promote antitumor 
immunity, and this depends on the presence of appropriate tran-
scription factors and cytokines (26). Our study demonstrates that 
expression of genes such as those coding for chemokine and che-
mokine receptors can be detected in archived primary tumors at 
the transcript level, offering a viable alternative to flow cytometry 
or cytokine assays in biomarker studies, given the practical limita-
tion of these assays in clinical settings (27).
By attributing a score to innate and adaptive immunity as previ-
ously defined (8), we were able to assess whether the immune cells 
characterizing each CIC were suggestive of a polarized response 
(Figure 2B). Although the innate and adaptive immune scores were 
very highly correlated, they were less so in intermediate immune/
keratin poor CIC3 (more adaptive) and intermediate immune/
keratin rich CIC5 (more innate), but the lack of survival difference 
in these 2 groups may indicate that any type of immune response 
is better than none, as has been implied in studies of outcomes 
from different immunotherapeutic regimes (28, 29). Moreover, the 
lack of survival differences between CICs 1, 2, 3, and 5 may also 
reflect the differences in prognostic histopathological features. As 
an example, multivariable analysis indicated that the good sur-
vival in low immune/keratin rich (CIC6) was in part determined 
by these factors (Tables 1 and 3). The most informative compari-
son is between intermediate immune/keratin poor CIC3 and low 
immune/β-catenin high CIC4, as they have similar histopathologi-
cal features (e.g., 52% and 49% ulcerated tumors, respectively, the 
highest mitotic rate of all clusters, and median Breslow thickness of 
2.7 and 3.2 mm, respectively; Table 1). The melanoma-specific sur-
vival was significantly worse in low immune/β-catenin high CIC4, 
however, and this was associated with lower immune scores and 
less histopathologist-reported brisk TILs.
The total immune score data were consistent with published 
literature (14, 18). Several individual immune cell scores showed 
a significant association with patient survival in univariable 
analysis, including T cells, cytotoxic cells, CD8+ T cells, B cells, 
follicular helper T (Tfh) cells, Th17 cells, and Th1 cells, which is 
consistent with existing literature (21, 30, 31). However, the high 
correlation between the scores for all immune cells as seen in 
Figure 1A makes it difficult to disentangle the role played by each 
of them. Although not significant after multiple testing and not 
replicated in TCGA, Th2 cell and eosinophil scores, and eosino-
phils were the only cell types with a nominally detrimental effect 
on survival (Table 6). Th2-mediated inflammation acting to pro-
mote tumors has been reported (32), and although its score had 
little variation across the CICs in our data, the Th1/Th2 ratio did 
vary and was lower in the poor prognostic cluster low immune/ 
β-catenin high. Drawing the data together, low immune/β-catenin 
high CIC4 had the lowest immune scores overall, the worst prog-
nosis, increased β-catenin signaling, increased levels of arginase 
2, and lower Th1/Th2 ratio, all consistent with a protumorigenic 
immunosuppressive microenvironment.
Treg scores showed little variation across the CICs, and we 
cannot exclude the possibility that this was due to the intrinsic 
limitation of using gene expression to infer immune cells (Tregs 
were represented by a single gene, FOXP3). There was some evi-
dence of higher Tregs in low immune/β-catenin low (CIC1), which 
had a low immune overall score but high CD56bright NK cells and 
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metastasis and of nodal normal lymphocytes in the nodal metasta-
ses. This sample set was too small to draw strong conclusions, but 
the evidence suggests that nonlymphatic tissues would be prefer-
able for metastasis immune profiling, and that metastatic tissue 
will likely have some signals from the host organ, which should be 
accounted for in their interpretation.
It has been reported in the gene, environment and melanoma 
(GEM; https://www.gemstudy.org/main/index.html) study that 
NRAS-mutated primaries are less likely to have brisk TILs on 
histopathological examination (19). Our data show that CD8+ T 
cell and NK cell scores had no protective effect in NRAS-mutated 
(codon 12, 13, or 61) tumors, some effect in BRAF-V600–mutated 
tumors, and the greatest effect in double-WT tumors, meaning 
that even when T cells are present they are much less effective in 
terms of survival in the presence of NRAS mutations. Since NRAS 
mutations are more frequent in tumors from older males, we ini-
tially suspected that these factors confounded the lack of asso-
ciation, but it persisted when we adjusted for age and sex, and 
we made similar observations in TCGA data. Some reports have 
suggested that NRAS mutations might predict a better response 
to immunotherapy and that NRAS-mutated tumors may express 
more PDL-1 (46). More recently, it was reported (47) that patients 
with BRAF-mutated melanoma were less likely to require com-
bined PD-1 and CTLA4 blockade than others, reinforcing the 
view that mutation status may predict response to checkpoint 
blockade. Our data do not support PDL-1 expression as a mecha-
nism explaining a differential response to T cell infiltration in 
tumors with different driver mutations.
In summary, we report the immune landscape of a large 
population-ascertained sample set of primary melanomas with 
replication in primary and metastatic disease. We identified 
subgroups with gene expression patterns indicative of different 
immune responses confirmed by pathologist-reported TILs. In 
42% of primary melanomas overall and 73% of those with the 
poorest outcome, we report a strong confirmation of a causal role 
for β-catenin signaling in immune response failure, resulting from 
epigenetic modifications, activating mutations, and DNA ampli-
fication. These data suggest that β-catenin signaling should be an 
important therapeutic target for the future and that immunothera-
py clinical trials should be stratified on driver mutations.
Methods
Transcriptomic data generation and preprocessing. FFPE melanoma 
tumor blocks were obtained from the population-ascertained Leeds 
Melanoma Cohort (LMC) (10, 11). Two thousand eighty-four patients 
were ascertained from pathology and clinical registers in a geographi-
cally defined area of the northern part of the United Kingdom, with 
additional recruitment from 32 other clinical centers carrying out sen-
tinel node biopsies (total 342 recruits) and rare subtypes of cases with 
melanomas arising in sun-protected sites (total 76 recruits). Patients 
were invited to participate at 3 months after diagnosis with the intent 
of interviewing and sampling them within the period 3–6 months after 
diagnosis. Patients responded variably quickly, and the median time 
to interview was 5.2 months. Seven hundred three of 2,184 tumors 
were sampled (see below). The median follow-up time at the end of 
this analysis is 7.5 years. Only 10 participants whose transcriptomes 
were analyzed have to date received BRAF inhibitors, 10 ipilimumab 
for CAF-derived arginase 2 in the immunosuppressive environ-
ment of low immune/β-catenin high CIC4. Because of shortage of 
matched tumor tissue, we were unable to explore protein expres-
sion of the arginases in this sample set.
Immune evasion via activation of β-catenin signaling was 
reported in human melanoma (43) using an earlier TCGA data 
release containing 266 metastatic melanomas. Here we have used 
a more recent release of TCGA data with 472 melanomas of which 
103 are primaries. Furthermore, in that earlier report, samples 
were split into 2 groups using a T cell signature (T cell inflamed and 
noninflamed), while we have used the Melanoma Immunome to 
develop a fuller picture of the tumor microenvironment, resulting 
in the identification of 6 CICs with different immunophenotypes. 
The association between β-catenin signaling and immune signa-
tures was replicated in this more heterogeneous TCGA data set 
and more notably in the LMC data set (all primaries). Important-
ly, mouse models have indicated that β-catenin signaling exerts 
immune evasion via downregulation of CCL4 and impaired traf-
ficking of BATF3-expressing CD103+ DCs (homologous to CD141+ 
DCs in humans), thus limiting T cell responses (26). Our study 
exposes this mechanism in 42% of primary melanomas overall 
and 73% of 1 particular subgroup with the poorest outcome (CIC4). 
Further mouse models have shown that DCs expressing CCR7 
play a critical role in antigen transport and T cell priming in lymph 
nodes (44) and that failure to recruit these DCs causes an upregula-
tion of β-catenin signaling; our data revealed significantly reduced 
expression of CCR7 in primary tumors classified as low immune/ 
β-catenin high CIC4 (Figure 2C), further supporting the view that 
increased β-catenin signaling may be pivotal in controlling DC-
mediated immune responses (26) and its therapeutic inhibition in 
conjunction with immunotherapy might be usefully explored.
The 6 CICs, their association with survival, and their charac-
teristic immunomodulatory profiles were replicated in TCGA data 
where the additional methylation, copy number, and mutation data 
showed consistency with transcriptomic data. Collectively, these 
data demonstrate the existence of amplifications, putative activat-
ing mutations, hypomethylation, and ultimately higher expression 
of different β-catenin signaling components in the tumor cluster 
with the least evidence of immune response (Figure 3). Further-
more, protein data (IHC and RPPA) confirmed the observations 
made at mRNA level for the key genes CTNNB1, CD274 (PDL-1), 
and LCK. The strength of this recapitulation is significant, as the 
LMC is made up of primary tumors while the TCGA melanoma 
data set is predominantly composed of metastases. Although we 
were unable to describe the cell distribution of proteins in the 
TCGA data set, similar results have been reported in lung cancer 
(45). Taken together, these data strongly suggest that genetic, epi-
genetic, and consequent transcriptomic modification of tumoral 
β-catenin signaling contributes to immune suppression in a signifi-
cant proportion of skin melanomas. Our study shows that immune 
signatures predict outcomes at the time of diagnosis of the primary, 
but that they also have the same predictive value for metastatic dis-
ease. We had 9 paired samples of primary and nodal/subcutaneous 
metastatic tumors in this study, and metastases tended to have a 
weaker immune response than their paired primaries, which is not 
surprising. For some of them, however, data suggested that host 
tissue signatures were detected, of keratin in the subcutaneous 
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HTB-65) cultured in house and in published melanocyte cultures (Gene 
Expression Omnibus [GEO] GSE4570). In each of these cell lines we 
considered as highly expressed any gene whose expression level ranked 
in the top 25% relative to the whole genome. The remaining genes 
(n = 380) and the cell types they represent (n = 24) after this filtering 
are referred to in this paper as the Melanoma Immunome. The follow-
ing abbreviated names were used to represent the cell types: iDC/aDC/
pDC, immature/activated/plasmacytoid DC; Tem, effector memory T 
cell; Tcm, central memory T cell; Tfh, follicular helper T cell; Tgd, γδ T 
cell; NKd, natural killer CD56dim cell; and NKb, natural killer CD56bright 
cell. An important feature of the original Immunome Compendium 
(8), and therefore also of the Melanoma Immunome, is that certain 
genes are specific not to a particular cell type but to several subtypes or 
a broader type of cell. For example, genes expressed by both NKb and 
NKd defined the broader NK cell phenotype. Genes expressed by all NK 
cell subtypes, CD8+ T cells, and Tgd cells were labeled cytotoxic genes, 
and genes expressed by various T cell subtypes (Th1, Th2, CD8+ T cell, 
Tem, Tcm) were labeled as broader T cell genes. This system allows 
scoring of generic cell types in addition to their more specific subtypes.
Tumor classification using the Melanoma Immunome. Using the 
Melanoma Immunome, we classified tumor samples using the con-
sensus cluster approach (12) in the training data set with the R pack-
age ConsensusClusterPlus (13). We used the KMeans algorithm with 
a maximum number of 12 clusters, the Euclidian distance, 80% genes 
and tumor resampling, and 5,000 repeats. The final number of clus-
ters was determined by examination of consensus cluster matrices, 
plots of consensus cumulative density function (CDF), and the change 
in the area under the CDF curve, i.e., ΔCDF (13). It is important to 
note that this clustering approach aimed to identify the best tumor 
groupings and did not generate gene clusters. Simply, then, to allow 
graphical representation, after choosing the optimal number of tumor 
clusters (consensus immunome clusters, or CICs), we also clustered 
the genes (1-pass without resampling) while fixing samples in their 
respective CICs. For this gene clustering analysis, we again used the 
KMeans algorithm and fixed K = 4, i.e., 4 gene clusters. This number 
was chosen to reflect 2 major immune responses, innate and adaptive, 
and their putative components with good or bad effect on outcome 
(56). The obtained tumor clusters in the training data set were repli-
cated in the test set using the supervised nearest centroid method (53, 
57) with the Spearman correlation similarity metric.
Scoring each cell subtype, innate, adaptive, and total immune function. 
We assigned a simple score to each cell type in each tumor as an aver-
age of the expression of all genes specific to that cell type, after stan-
dardizing the expressions to mean 0 and variance 1. We then rescaled 
each cell score to a range of 0–1. To obtain the total immune score per 
tumor, we added together scores from all 24 cell subtypes. For innate 
and adaptive scores, we added immune scores from each type accord-
ing to Bindea et al. (8): NK, NKb, NKd, DC, aDC, iDC, pDC, mast 
cells, macrophages, eosinophils, and neutrophils for innate immunity; 
B cells, T cells, CD8+ T cells, cytotoxic cells, Th, Tfh, Th1, Th2, Th17, 
Treg, Tcm, Tem, and Tgd for adaptive immunity. To evaluate this scor-
ing scheme, we plotted key immune cell scores alongside the CICs, and 
the innate versus the adaptive immune score, and compared the total 
score with an equivalent score calculated using the published software 
ESTIMATE (18). Similarly, we plotted this total immune score along-
side the molecular phenotypes inferred in our data using 2 published 
gene signatures by Jonsson et al. (14) and TCGA (15).
and 2 pembrolizumab, so the data reflect essentially treatment-naive 
patients. Histopathological factors associated with survival such as 
Breslow thickness and ulceration status were as clinically reported. 
Three measures of tumor-infiltrating lymphocytes (TILs) were used: 
first, TILs as classified by Clark et al. (48) and recently clarified by 
Schatton et al. (1) and reported by specialist histopathologists in the 
clinical service; second, TILs scored by a blinded single observer in 
the research group (S. O’Shea)in the whole tumor slide; and third, 
TILs also graded by a single observer (S. O’Shea) in the area of the tis-
sue cored for RNA extraction. These were scored with a 4-grade score 
from “lots” to “none/barely perceptible.” Follow-up data were ascer-
tained by examination of hospital medical notes, primary care records, 
annual questionnaires from consenting participants, and cancer regis-
tries, and melanoma-specific survival data were derived.
The tumor blocks were sampled horizontally using a 0.6-mm 
microarray needle as marked by J. Newton-Bishop. J. Newton-Bishop 
reviewed all H&E sections of primary tumors and marked deep invasive 
tumor, which was the least stromally rich and least inflamed, to allow 
comparison within the data set. Where large tumors were available 
the ethical approval allowed sampling using up to 2 cores, which were 
chosen to be most similar areas of the tumor. The mRNA was extracted 
from 820 tumor cores (703 unique patients and 117 duplicates) as pre-
viously described (49, 50), and gene expression was quantified using 
the Illumina DASL Human HT12 v4 array. The data were deposited 
into the European Genome-phenome Archive (EGA) (accession no. 
EGAS00001002922). Paired sample transcriptomes were available 
from 9 patients: 9 paired primary and soft tissue metastases.
GenomeStudio was used to extract raw data from the image files. 
Data were background-corrected and quantile-normalized using the 
package Lumi (51) in R. Singular value decomposition (SVD) was 
applied in Swamp R package (52) to assess the association between 
top principal components and technical variables such as batch, chip, 
age of FFPE block, and RNA concentration. Technical variables found 
to be associated with these top components were adjusted out, and 
SVD was reapplied with and without data permutation to appraise the 
remaining “biological” variability in the data. Normalized full-inten-
sity plots were examined to detect outliers. Among sample duplicates, 
we retained in the final data set the sample with the highest number of 
detected genes. Overall, the median and interquartile range of detect-
ed genes per sample at P less than 0.05 were 14,784 (range 14,153–
15,304), consistent with other studies using DASL arrays in melanoma 
(14, 53–55). After quality control, genes were standardized to a mean 
0 and variance 1, and samples were randomly split into a training set 
(two-thirds) and a test set (one-third). Subsequently, when the analy-
sis revealed similar results between the training and test sets, the total 
pooled data set was used in downstream analyses.
Derivation of Melanoma Immunome. Bindea et al. (8) derived the 
Immunome Compendium from their own and published data on genes 
expressed by FACS-sorted immune cells. Genes that appeared to be 
expressed only by specific immune cell subsets were used to define the 
presence of those cell subtypes in the tumor. A total of 577 genes was 
included in the Immunome Compendium, encompassing those spe-
cific to each of 24 immune cell types and some control tissues: SW480 
colon cancer cell line, normal mucosae, blood, and lymphatic vessels 
(8). From this list, we excluded genes expressed by these control tissues, 
and we further eliminated all genes that we found highly expressed in 
melanoma cell lines SK-MEL-28 (ATCC HTB-72) and MEWO (ATCC 
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As a sensitivity analysis, we combined TCGA primary tumors (n = 103) 
with the total LMC sample (all primaries) and conducted a new con-
sensus cluster analysis with the same parameters (80% gene and tumor 
resampling, KMeans algorithm with K = 12 and Euclidian distance, 4 
gene clusters) and compared the results with the initial analysis. Gene 
promoter methylation data were compared with RNA-Seq data for the 
β-catenin pathway genes to assess the epigenetic contribution to gene 
expression. Copy number alterations and point mutations were plotted 
alongside gene expression and the CICs for genes in the β-catenin sig-
naling pathway using the OncoPrint graph function (63) to assess the 
role of structural modification in the regulation of immune evasion. 
The genes for OncoPrint representation were chosen based on fre-
quency of mutations and alterations with a cutoff of 4%. Enrichment 
in these genetic alterations and mutations within a particular CIC com-
pared with the others was tested using Fisher’s exact test. β-Catenin 
pathway score was generated as in the LMC data set using the expres-
sion of 9 genes (gxscore). The pathway methylation score was generated 
as methylscore = ∑(1 – β), where β = proportion of methylated CpG sites. 
The mutation and copy number score was generated as mutCNVscore = 
∑(I + J), where I = 1 if the gene has a putative activating mutation and 
0 otherwise, and J = –1 if the gene is deleted, +1 if it is amplified, and 0 
otherwise. In each of these scores, the sum is over the 9 genes (CTN-
NB1, c-MYC, APC, APC2, SOX2, SOX11, TCF1, TCF12, and VEGFA). 
To test additive value of these different data types, these scores were 
combined (gxscore + methylscore, then gxscore + methylscore + mutCNVscore), 
and their variation across tumor clusters was evaluated.
IHC staining and protein data validation. In a subset of the LMC, 
we ran the IHC staining for β-catenin (33 tumors) and its membranous 
ligand E-cadherin (37 tumors). Under the terms of our study ethical 
approval and the consent given by the participants, we had access only 
to stored tumor blocks from participants who had died of melanoma or 
other causes (the intent being to conserve tumor blocks for clinical test-
ing). The tumor set examined was therefore small and somewhat biased 
in favor of poor-prognosis tumors. The slides were therefore used just to 
compare gene expression results with level of protein expressed. 
Staining. After the melanoma FFPE blocks were sampled, 5-μm 
sections were cut and mounted onto Superfrost Plus slides (Thermo 
Fisher Scientific) and underwent IHC staining using IntelliPath FLX 
detection reagents (MenaPath, A. Menarini Diagnostics). Antigen 
retrieval by heat was performed in Access Revelation (pH 6.4), fol-
lowed by peroxidase quenching and background blocking with casein. 
Tissue sections were incubated with antibodies raised against human 
β-catenin (9562, New England Biolabs) or E-cadherin (14472, New 
England Biolabs) followed by MenaPath HRP-polymer or Universal 
Probe and HRP-polymer, respectively. IHC labeling was detected 
using MenaPath purple chromogen.
Scoring. Light microscopy (×10 magnification) was used to assess 
expression of β-catenin and E-cadherin. Staining scores for the regions 
immediately surrounding the tumor core “punch hole” were recorded. 
In those tumors that were cored twice (and hence had 2 punch holes), 2 
staining scores were generated; where these were discordant, the slides 
were not used for subsequent analyses. For β-catenin, 3 staining scores 
were measured as determined by the cellular localization — overall, 
cytoplasmic, and membranous. Each was assessed on a scale of 0–3 and 
was used to measure both the intensity and the distribution of staining 
surrounding the cored tumor region (0, no staining; 1, weak staining; 
2, intermediate staining; 3, high intensity and distribution of staining). 
Statistical analyses of the CICs and immune scores. Kaplan-Meier plots 
and Cox proportional hazards regression were used to analyze the dif-
ference in survival between the CICs. We compared the CICs for clinical 
melanoma characteristics using the Kruskal-Wallis test for continuous 
variables and χ2 or Fisher’s exact tests for categorical variables. Multi-
variable survival analysis was conducted, testing the joint effects of the 
CICs and up to 8 histological variables (age, sex, tumor site, AJCC stage, 
Breslow thickness, ulceration, mitotic rate, vascular invasion, BRAF 
and NRAS mutation status) in the Cox model. We also tested the added 
prognostic value of the CICs compared with the expression of CD8A and 
CD8B in Cox proportional hazards model, i.e., whether the CICs are a 
simple reflection of a T cell function. The association between immune 
cell scores and genes coding for a range of checkpoint/inhibitory mole-
cules was assessed and represented graphically as a heatmap. We consid-
ered genes coding for the most studied immune checkpoint coinhibitors: 
programmed cell death 1 (PD-1), its ligands PDL-2 and PDL-1 (also known 
as CD274), and cytotoxic T lymphocyte–associated protein 4 (CTLA4); 
along with a representative set of other negative regulators of immune 
responses emerging as new targets of immunotherapies currently in 
clinical trials: T cell immunoglobulin and mucin-domain containing-3 
(TIM-3; also called hepatitis A virus cellular receptor 2 [HAVCR2]), 
lymphocyte activation gene 3 (LAG3), and V-domain immunoglobulin- 
containing suppressor of T cell activation (VISTA; encoded by the 
C10orf54 gene) as well as B and T lymphocyte attenuator (BTLA) (58–
61). We also included the immunosuppressive enzymes indoleamine 
2,3-dioxygenase 1 and 2 (IDO1, IDO2), which are being tested as immu-
notherapy targets in clinical trials (62), and expanded our list to other 
immunological targets such as CD40, CD200, TNFRSF4, TNFRSF18, 
TNFRSF9, CD72, CD27, ARG1, ARG2, KIR3DL1, and ICOS.
To investigate immune cell association with the β-catenin signal-
ing pathway, we plotted the expression of key genes from this path-
way (43) on the cell scores heatmap. There is published evidence that 
when expressing CCR7, CD141+ DCs drive intratumoral T cell activa-
tion (44), and that failure to recruit these cells is causally related to 
increased β-catenin signaling. To assess whether these mechanisms 
would be detectable in archived primary tumors, we assessed the asso-
ciation between expression of IRF8, BATF3, and CCR7, DC score, T 
cell score, and expression of genes from the β-catenin signaling path-
way. To derive the proportion of tumors with evidence of upregulated 
β-catenin expression in this population cohort, we used the means test 
of X-tile (17) to generate an optimal cutoff value of CTNNB1 that bet-
ter predicts the variation in T cell score. We also generated a score for 
the β-catenin signaling pathway as sum of standardized expressions 
of CTNNB1, c-MYC, APC, APC2, SOX2, SOX11, TCF1, TCF12, and 
VEGFA (43), i.e., gxscore = ∑gx, where gx = standardized gene expression 
and the sum is over the 9 genes listed.
Replication in TCGA. We downloaded The Cancer Genome Atlas 
cutaneous melanoma data from cBioPortal (http://www.cbioportal.
org/data_sets.jsp), including RNA-Seq expression, copy number altera-
tions, DNA promoter methylation, and the mutations. To replicate the 
cluster analysis, each tumor was assigned to one CIC by application 
of the nearest centroid method (53, 57) to RNA-Seq data. Cox propor-
tional hazards regression was used in overall survival analysis compar-
ing the CICs, unadjusted and adjusting for other prognostic factors. 
Association of the CICs with expression of genes encoding checkpoint 
coinhibitors, immunomodulatory enzymes, and transcription factors 
and β-catenin signaling was conducted in the same way as in the LMC. 
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Study approval. The Leeds Melanoma Cohort was reviewed by the 
North East – York Research ethics committee (Jarrow, Tyne and Wear, 
UK) and received ethical approval MREC 1/3/57, PIAG 3-09(d)/2003. 
All participants gave written informed consent prior to their participa-
tion in the study.
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For E-cadherin, the membranous staining intensity was homogenous 
for most tumors and was attributed a score based on the distribution of 
staining on a scale of 0–3 (0, no staining; 1, weak staining; 2, intermedi-
ate staining; 3, high distribution). Statistical analyses were conducted 
comparing the level of staining and mRNA expression (Kruskal-Wallis 
test). When 2 or more consecutive levels of staining showed no dif-
ference between them, they were pooled together to have fewer cat-
egories and reduce random variation. Scoring was developed by pairs 
of observers (J. Newton-Bishop and 1 other) and standards identified. 
J. Newton-Bishop and 1 other then scored slides separately (blind to 
gene expression status), and differences were resolved.
We also downloaded protein-level data (Reverse Phase Protein 
Array, RPPA; http://tcpaportal.org/tcpa/download.html) for 354 of 
the 472 TCGA skin melanomas. RPPA measures protein levels on a 
continuous scale, and we selected the key immune genes LCK and 
CD274 (PDL-1) as well as β-catenin and E-cadherin to assess the cor-
relation between protein-level data and mRNA expressions. We also 
tested the difference in protein-level data between tumor clusters.
Statistics. A range of analyses are described in the relevant sec-
tions of Methods. Where required, confounding factors were adjusted 
for, and multiple testing was dealt with by Bonferroni correction. Non-
parametric methods (Kruskal-Wallis, Mann-Whitney, Fisher’s exact 
test, and Spearman correlation) were used; 1-way ANOVA was used to 
estimate the proportion of variance explained. Cox regression and log-
rank tests were used in survival analyses. Two-sided tests were applied 
throughout, and a P value below 0.05 (after multiple-testing adjust-
ment where required) was considered significant.
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